Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 20, Issue 1, 1997, Pages 49-51

  Wingard, J R ^a   Nash, R A ^b   Ratanatharathorn, V ^c   Fay, J W ^d   Klein, J L ^e   Przepiorka, D ^f   Maher, R M ^g   Devine, S M ^h   Boswell, G ^g   Bekersky, I ^g   Fitzsimmons, W ^g  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Fujisawa USA Inc   (United States)

^h ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

FK506; Graft versus host disease; Methotrexate; Tacrolimus

Indexed keywords

CYCLOSPORIN; METHOTREXATE; PRISTINAMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0030742833     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700839     Document Type: Article

References (8)

1. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
2. Fay JW, Wingard JR, Antin JH et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87: 3514-3519.
3. Ratanatharathorn V, Nash RA, Devine SM et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling bone marrow transplantation (BMT). Blood 1996; 88 (Suppl. 1): 459a (Abstr. 1826).
4. Thyss A, Milano G, Renée N et al. Severe interaction between methotrexate and a macrolide-like antibiotic. J Natl Cancer Inst 1993; 85: 582-583 (letter).
5. Dix SP, Devine SM, Geller RB et al. Lack of clinically significant interaction between low dose methotrexate and tacrolimus or cyclosporine in the bone marrow transplant setting. J Natl Cancer Inst 1995; 87: 1641 (letter).
6. Fluorescence Polarization Assay for FK506, Tdx Assays Manual. Publication R-107. Abbott Laboratories, IL, USA, 1991.
7. Evans WE, Crom WR, Yalowich JC. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ (eds). Applied Pharmacokinetic, Principles of Therapeutic Drug Monitoring. Applied Thera-peutics: Vancouver, 1992, pp 1009-1056.
8. Nevill TJ, Tirgan MH, Deeg HJ et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 349-354.